Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 9/20 | 0.80 |
| ▸ | EGFR | P00533 | 15/20 | 0.75 |
| ▸ | GAK | O14976 | 3/20 | 0.75 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.75 |
| ▸ | BUB1 | O43683 | 2/20 | 0.75 |
| ▸ | STK10 | O94804 | 2/20 | 0.75 |
| ▸ | ABL1 | P00519 | 2/20 | 0.75 |
| ▸ | LCK | P06239 | 2/20 | 0.75 |
| ▸ | LYN | P07948 | 2/20 | 0.75 |
| ▸ | RET | P07949 | 2/20 | 0.75 |
| ▸ | SRC | P12931 | 2/20 | 0.75 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.75 |
| ▸ | FECH | P22830 | 2/20 | 0.75 |
| ▸ | KDR | P35968 | 2/20 | 0.75 |
| ▸ | FLT3 | P36888 | 2/20 | 0.75 |
| ▸ | MAP3K1 | Q13233 | 2/20 | 0.75 |
| ▸ | PLK4 | O00444 | 1/20 | 0.75 |
| ▸ | CIT | O14578 | 1/20 | 0.75 |
| ▸ | AURKA | O14965 | 1/20 | 0.75 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642967 | 1.00 | ERBB2 (0.80) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL642902 | 0.94 | EGFR (0.79) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL643068 | 0.94 | EGFR (0.79) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL4412308 | 0.94 | EGFR (0.79) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL643681 | 0.91 | HDAC3 (0.79) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL12518963 | 0.90 | EGFR (0.66) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL8209586 | 0.89 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL8205021 | 0.89 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL4893540 | 0.89 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2BUB1 | |
| SCHEMBL641997 | 0.89 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS INC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9024024-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2015-05-05 | — | — | US | disclosed |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8604044-B2 | Quinazoline based EGFR inhibitors containing a zinc binding moiety | CURIS, INC. (US) | 2013-12-10 | — | — | US | disclosed |
| EP-2061772-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-2061773-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | Curis, Inc. (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | CURIS, INC. | 2008-09-11 | — | — | US | disclosed |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | CURIS, INC. | 2008-08-14 | — | — | US | disclosed |
| WO-2008033747-A9 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS INC (MA) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008033749-A2 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033747-A2 | MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS | CURIS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221132-A1 | Multi-Functional Small Molecules as Anti-Proliferative Agents | HDAC1, HDAC6, HDAC5 | ERBB2 2794/4885EGFR 2358/4885GAK 215/4885 |
| US-20140221403-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, HDAC5, ERBB4 | ERBB2 7/4885EGFR 1/4885GAK 179/4885 |
| US-20080194578-A1 | inhibitors of epidermal growth factor receptor tyrosine kinase and histone deacetylase; 2-(4-(3-Chloro-4-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyacetamide; anticarcinogenic agent | HDAC1, HDAC8, EGFR | ERBB2 9/4885EGFR 3/4885GAK 105/4885 |
| US-20150284340-A1 | QUINAZOLINE BASED EGFR INHIBITORS CONTAINING A ZINC BINDING MOIETY | EGFR, ERBB4, HDAC5 | ERBB2 7/4885EGFR 1/4885GAK 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.